Gene Expression, Molecular Class Changes, and Pathway Analysis after Neoadjuvant Systemic Therapy for Breast Cancer
暂无分享,去创建一个
G. Mills | G. Hortobagyi | L. Pusztai | K. Do | W. Symmans | F. Meric-Bernstam | A. González-Angulo | F. Symmans | Shuying Liu | T. Iwamoto | Huiqin Chen | Kim Anh Do
[1] Hui Gao,et al. Expression of epithelial–mesenchymal transition‐inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy , 2011, International journal of cancer.
[2] T. Mak,et al. Regulation of cancer cell metabolism , 2011, Nature Reviews Cancer.
[3] Yuan Qi,et al. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Jeffrey M. Rosen,et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features , 2009, Proceedings of the National Academy of Sciences.
[5] A. Nobel,et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Achim Rody,et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers , 2009, Breast Cancer Research.
[7] Achim Rody,et al. T cell marker metagene predicts a favourable prognosis in estrogen receptor negative and Her2 positive breast cancers. , 2009 .
[8] K. Hess,et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] G. Hortobagyi,et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer , 2008, Breast Cancer Research and Treatment.
[10] D. Berry,et al. Research issues affecting preoperative systemic therapy for operable breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Lajos Pusztai,et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. , 2007, The Lancet. Oncology.
[13] Zhen Jiang,et al. Bioconductor Project Bioconductor Project Working Papers Year Paper Extensions to Gene Set Enrichment , 2013 .
[14] R. Tibshirani,et al. On testing the significance of sets of genes , 2006, math/0610667.
[15] Lajos Pusztai,et al. Reproducibility of Gene Expression Signature–Based Predictions in Replicate Experiments , 2006, Clinical Cancer Research.
[16] G. Hortobagyi,et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Roman Rouzier,et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.
[18] K. Coombes,et al. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. , 2005, The Journal of molecular diagnostics : JMD.
[19] J. V. Von Roenn,et al. Final results of a phase II trial of preoperative TAC (docetaxel/doxorubicin/cyclophosphamide) in stage III breast cancer. , 2005, Clinical breast cancer.
[20] Terry L. Smith,et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Stec,et al. Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma , 2003, Cancer.
[22] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] Kevin R Coombes,et al. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. , 2012, European journal of cancer.
[24] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Cheng Li,et al. Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.
[26] Baljit Singh,et al. A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. , 2003, Clinical Cancer Research.